Genetic/familial high-risk assessment: breast and ovarian, version 1.2014

J Natl Compr Canc Netw. 2014 Sep;12(9):1326-38. doi: 10.6004/jnccn.2014.0127.


During the past few years, several genetic aberrations that may contribute to increased risks for development of breast and/or ovarian cancers have been identified. The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian focus specifically on the assessment of genetic mutations in BRCA1/BRCA2, TP53, and PTEN, and recommend approaches to genetic testing/counseling and management strategies in individuals with these mutations. This portion of the NCCN Guidelines includes recommendations regarding diagnostic criteria and management of patients with Cowden Syndrome/PTEN hamartoma tumor syndrome.

Publication types

  • Practice Guideline

MeSH terms

  • Disease Management
  • Female
  • Genetic Counseling
  • Genetic Testing
  • Germ-Line Mutation
  • Hamartoma Syndrome, Multiple / diagnosis*
  • Hamartoma Syndrome, Multiple / genetics*
  • Humans
  • Male